Akers Biosciences Inc (AKER)

0.532 +0.0331 (+6.635%)

IEX Real-Time Price

February 23, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 0.4989

Price Open 0.55

Volume: 16.23M

Avg Volume: 21.33M

Market Cap: 16.72M

P/E Ratio -

52 Wk Range 0.122-2.9



AKER Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-01-31
30.56M
9.29M
0.61
30.39%

2018-01-12
30.56M
918,119
0.12
3.00%

2017-12-29
30.75M
194,099
0.09
0.63%

2017-12-15
31.42M
529,598
1.58
1.69%




News

Akers' equity offering sinks shares, down 61% (2017-12-19 10:56 SeekingAlpha)

Thinly traded nano cap Akers Biosciences ( AKER -61.4% ) slumps on a 23x surge in volume in response to its $6M public equity offering . More news on: Akers Biosciences Inc., Healthcare stocks news, Stocks on the move, Read more …

 

Akers Biosciences' (AKER) CEO John Gormally on Q3 2017 Results - Earnings Call Transcript (2017-11-15 14:11 SeekingAlpha)

Akers Biosciences, Inc. (AKER) Q3 2017 Results Conference Call November 15, 2017 09:00 AM ET Executives Ben Simons - Global Public Relations Manager, Vigo Communications John Gormally - CEO Dr. Ray Akers - Executive Chairman & Chief Scientific Director Gary Rauch - VP, Fina…

 

Akers Biosciences reports Q3 results (2017-11-15 07:04 SeekingAlpha)

Akers Biosciences (NASDAQ: AKER ): Q3 EPS of -$0.13 More news on: Akers Biosciences Inc., Earnings news and commentary, Healthcare stocks news, , Read more …

 

Akers Biosciences' (AKER) CEO John Gormally on Q2 2017 Results - Earnings Call Transcript (2017-08-15 13:22 SeekingAlpha)

Start Time: 09:00 End Time: 09:27 Akers Biosciences, Inc. (AKER) Q2 2017 Earnings Conference Call August 15, 2017, 09:00 AM ET Executives John Gormally - CEO Ray Akers - Vice Chairman Gary Rauch - VP, Finance Ben Simons - Global Public Relations Manager, Vigo Communications…

 

Akers Biosciences reports Q2 results (2017-08-15 05:45 SeekingAlpha)

Akers Biosciences (NASDAQ: AKER ): Q2 EPS of -$0.08 More news on: Akers Biosciences Inc., Earnings news and commentary, Healthcare stocks news, , Read more …

 

Akers Biosciences' (AKER) CEO John Gormally on Q1 2017 Results - Earnings Call Transcript (2017-05-16 12:21 SeekingAlpha)

Akers Biosciences Inc. (AKER) Q1 2017 Earnings Conference Call May 16, 2017 09:00 AM ET Executives Fiona Henson - Global Public Relations Manager, Vigo Communications John Gormally - Chief Executive Officer Ray Akers - Vice Chairman Gary Rauch - Vice President, Finance Analy…

 


Statistics

Shares Outstanding: 31.42M

Top 15 Institution Percent: 27.70

Price To Sales: 6.17

Price To Book: 3.97

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -74.64

Return On Equity: -100.21

Profit Margin: N/A

Price History

Beta: -117.79

50-day Moving Avg: 0.28

200-day Moving Avg: 0.84

YTD Change: N/A

5-day Change: 35.03

1-month Change: 126.29

3-month Change: -1.66

6-month Change: -44.00

1-year Change: -55.67

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Akers Biosciences Inc

Exchange: NASDAQ Capital Market

Industry: Medical Instruments & Equipment

Sector: Healthcare

Website: http://www.akersbio.com

Akers Biosciences Inc is engaged in the development and sale of disposable diagnostic testing device. The Company develops, manufactures, and supplies rapid, point-of-care screening and testing products.